BC
SNDX icon

Bridgefront Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Bridgefront Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$727K Buy
31,101
+11,349
+57% +$247K 0.18% 190
2025
Q4 		$415K Sell
19,752
-2,096
-10% -$36.6K 0.1% 312
2025
Q3 		$336K Buy
+21,848
New +$286K 0.1% 358
2024
Q4 		– Sell
-20,346
Closed -$392K – 770
2024
Q3 		$392K Buy
+20,346
New +$420K 0.15% 254

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Bridgefront Capital's SNDX Position: Q1 2026 in Review

Bridgefront Capital increased its Syndax Pharmaceuticals (SNDX) stake by 57% in Q1 2026, buying an estimated $247K and bringing the position to 31,101 shares worth $727K. The position accounts for 0.18% of the portfolio, ranked #190.

Bridgefront Capital first reported a position in SNDX in Q3 2024 and has held it in 4 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Bridgefront Capital held 31,101 shares of Syndax Pharmaceuticals worth $727K as of Q1 2026.
  • Bridgefront Capital bought 11,349 Syndax Pharmaceuticals shares in Q1 2026, an estimated $247K.
  • Syndax Pharmaceuticals made up 0.18% of Bridgefront Capital's portfolio in Q1 2026, its #190 holding.
  • Bridgefront Capital first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.